by Peter Ciszewski | Jan 10, 2022
Philippe Duchateau, PhD, Chief Scientific Officer at Cellectis, discusses the company’s gene editing technology which could potentially treat rare diseases such as sickle cell anemia. Sickle cell anemia is an inherited blood disorder. Early symptoms usually...
by Peter Ciszewski | Jan 8, 2022
William D. Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses what physicians ought to know about tenosynovial giant cell tumors (TGCT). TGCT are a group of rare, benign tumors that involve the synovium,...
by Peter Ciszewski | Jan 6, 2022
Paolo Ghia, MD, PhD, Professor at the Università Vita-Salute San Raffaele, Milan, Italy, and Director of the Strategic Research Program on CLL, discusses the difference between disease-free survival (DFS) and progression-free survival (PFS) within the context...
by Peter Ciszewski | Jan 5, 2022
Jeffrey A. Zonder, MD, hematologist-oncologist at the Barbara Ann Karmanos Cancer Institute in Detroit, Michigan, discusses data from the first-in-human study testing REGN5458 as a monotherapy for relapsed/refractory multiple myeloma patients (NCT03761108)....
by Peter Ciszewski | Dec 28, 2021
Anthony Quinn, PhD, President and CEO of Aeglea BioTherapeutics, provides an overview of Arginase 1 (ARG1) deficiency. As Dr. Quinn explains, ARG1 deficiency is a rare genetic disorder characterized by complete or partial lack of the enzyme arginase in the...
